Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ABEO
stocks logo

ABEO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.342
+144.05%
--
--
-0.130
-45.83%
--
--
-0.113
-106.63%
Estimates Revision
The market is revising Downward the revenue expectations for Abeona Therapeutics Inc. (ABEO) for FY2025, with the revenue forecasts being adjusted by -78.03% over the past three months. During the same period, the stock price has changed by -29.32%.
Revenue Estimates for FY2025
Revise Downward
down Image
-78.03%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-6.16%
In Past 3 Month
Stock Price
Go Down
down Image
-29.32%
In Past 3 Month
Wall Street analysts forecast ABEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABEO is 22.17 USD with a low forecast of 19.00 USD and a high forecast of 27.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ABEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABEO is 22.17 USD with a low forecast of 19.00 USD and a high forecast of 27.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.870
sliders
Low
19.00
Averages
22.17
High
27.50
Current: 4.870
sliders
Low
19.00
Averages
22.17
High
27.50
Stifel
Stephen Willey
Buy
downgrade
$20 -> $19
2025-11-12
Reason
Stifel
Stephen Willey
Price Target
$20 -> $19
2025-11-12
downgrade
Buy
Reason
Stifel analyst Stephen Willey lowered the firm's price target on Abeona Therapeutics to $19 from $20 and keeps a Buy rating on the shares. Management's temporary pause on patient biopsy collection sets back the commercial launch by about three months and decreases confidence in the firm's now-lower Q4 estimate as a result of the temporal uncertainty associated with the timing of revenue recognition, the analyst tells investors in a research note. The firm added that increasing patient demand strengthens its confidence in FY26 and beyond, and believes the set-up here offers an attractive risk/reward.
Oppenheimer
Oppenheimer
Outperform
maintain
$19 -> $20
2025-08-15
Reason
Oppenheimer
Oppenheimer
Price Target
$19 -> $20
2025-08-15
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Abeona Therapeutics to $20 from $19 and keeps an Outperform rating on the shares following quarterly results and business update highlighting launch progress for Zevaskyn, after the FDA approval in April. Q2 ending cash was bolstered by the sale of Abeona's PRV during the quarter for $155M, ending Q2 with $226M.
Oppenheimer
Oppenheimer
Outperform
initiated
$19
2025-06-02
Reason
Oppenheimer
Oppenheimer
Price Target
$19
2025-06-02
initiated
Outperform
Reason
Oppenheimer assumed coverage of Abeona Therapeutics with an Outperform rating and $19 price target. The firm notes Abeona's Q1 update highlighted strong early momentum following ZEVASKYN's April approval. The first Qualified Treatment Center has been activated ahead of schedule with the first patient on track for treatment in Q3 2025. Enthusiasm from patients/caregivers and physicians remains high. Notably, management highlighted strong interest at the SID conference, Oppenheimer adds. Based on the early launch progress, the firm's confidence in ZEVASKYN's commercial trajectory is reaffirmed.
Stifel
Stephen Willey
Buy
downgrade
$21 -> $20
2025-05-16
Reason
Stifel
Stephen Willey
Price Target
$21 -> $20
2025-05-16
downgrade
Buy
Reason
Alliance Global Partners
analyst
Buy
maintain
$25
2025-05-15
Reason
Alliance Global Partners
analyst
Price Target
$25
2025-05-15
maintain
Buy
Reason
Alliance Global Partners raised the firm's price target on Abeona Therapeutics to $27.50 from $25 and keeps a Buy rating on the shares. Abeona announced Q1 results following the recent news of their FDA approval for Zevaskyn, a gene therapy for recessive dystrophic epidermolysis bullosa, notes the analyst, who also points out that the company recently entered into an agreement to sell the Rare Pediatric Disease Priority Review Voucher it was granted for $155M, allowing for additional funding. The firm values Zevaskyn for RDEB at $24 per share and the remaining pipeline, which includes ABO-102 for Sanfilippo syndrome and three preclinical programs, and cash at $3.50 per share.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$15
2025-03-24
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$15
2025-03-24
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Abeona Therapeutics Inc (ABEO.O) is -7.92, compared to its 5-year average forward P/E of -0.15. For a more detailed relative valuation and DCF analysis to assess Abeona Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.15
Current PE
-7.92
Overvalued PE
28.83
Undervalued PE
-29.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
175.09
Current PS
0.00
Overvalued PS
429.62
Undervalued PS
-79.44
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 5109.96% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 5109.96% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ABEO News & Events

Events Timeline

(ET)
2025-12-01
07:40:00
Abeona Grants 45,685 Restricted Shares to New Employees
select
2025-11-12 (ET)
2025-11-12
07:33:23
Abeona Therapeutics projects more than two years of financial stability.
select
2025-11-12
07:32:56
Abeona Therapeutics announces Q3 earnings per share of 10 cents, falling short of the consensus estimate of 34 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-18Yahoo Finance
Epidermolysis Bullosa Market Analysis 2025-2035: Innovations by Abeona, Castle Creek, RHEACELL, and Chiesi Drive Growth in Gene Therapies and Advanced Wound Care

  • Market Dynamics: The Epidermolysis Bullosa (EB) market is experiencing growth due to increased awareness of the disease, advancements in genetic research, and innovative treatments like gene therapies and advanced wound care products.

  • Key Players and Innovations: Companies such as Abeona Therapeutics and Castle Creek Biosciences are leading the market by developing new therapies and medical devices, focusing on regenerative medicine and personalized care to improve patient outcomes.

  • Challenges in Treatment: Despite promising advancements, challenges remain, including high treatment costs, limited diagnostic tools, and the rarity of EB, which complicates funding and research efforts.

  • Emerging Trends: The market is seeing a shift towards regenerative medicine and advanced wound care solutions, with a focus on stem cell therapies and specialized products designed to enhance healing and improve the quality of life for EB patients.

[object Object]
Preview
9.5
11-12Newsfilter
Abeona Therapeutics® Announces Financial Results and Corporate Updates for Q3 2025

  • ZEVASKYN Treatment Timeline: The anticipated start of patient treatment with ZEVASKYN has been shifted to the fourth quarter of 2025 due to the optimization of a release assay, although patient demand remains strong with over 30 eligible patients identified at treatment centers.

  • Financial Position: As of September 30, 2025, Abeona Therapeutics reported $207.5 million in cash and equivalents, expected to fund operations for over two years, despite a net loss of $5.2 million for the third quarter.

  • Market Access and Demand: There is significant early market acceptance for ZEVASKYN, with coverage decisions from major commercial health plans covering approximately 60% of RDEB patients, and a permanent J-code established by CMS effective January 1, 2026.

  • Corporate Developments: Abeona has strengthened its management team with the appointment of a new Head of Clinical Development and has selected its ABO-503 gene therapy for participation in the FDA's Rare Disease Endpoint Advancement Pilot Program.

[object Object]
Preview
9.5
11-11NASDAQ.COM
KalVista, Health Catalyst, and Bio-Techne Experience After-Hours Increases Following Earnings Reports

  • Healthcare and Biotech Stock Gains: Several healthcare and biotech stocks saw significant increases in after-hours trading following earnings updates, with KalVista Pharmaceuticals rising 11.29% and Health Catalyst up 13.24%.

  • KalVista Pharmaceuticals Performance: The company reported a third-quarter net loss of $49.5 million, with net product revenue of $13.7 million, reflecting a larger loss compared to the previous year.

  • Health Catalyst Financials: Health Catalyst posted a third-quarter net loss of $22.2 million and a revenue decline to $76.3 million, while projecting Q4 2025 revenue of approximately $73.5 million.

  • Assertio Holdings and Other Stocks: Assertio Holdings reported a net income of $11.4 million, leading to an 8.30% stock increase, while Abeona Therapeutics is set to report its third-quarter results soon, with analysts expecting a loss.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Abeona Therapeutics Inc (ABEO) stock price today?

The current price of ABEO is 4.87 USD — it has increased 2.96 % in the last trading day.

arrow icon

What is Abeona Therapeutics Inc (ABEO)'s business?

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

arrow icon

What is the price predicton of ABEO Stock?

Wall Street analysts forecast ABEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABEO is 22.17 USD with a low forecast of 19.00 USD and a high forecast of 27.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Abeona Therapeutics Inc (ABEO)'s revenue for the last quarter?

Abeona Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Abeona Therapeutics Inc (ABEO)'s earnings per share (EPS) for the last quarter?

Abeona Therapeutics Inc. EPS for the last quarter amounts to -0.10 USD, decreased -84.13 % YoY.

arrow icon

What changes have occurred in the market's expectations for Abeona Therapeutics Inc (ABEO)'s fundamentals?

The market is revising Downward the revenue expectations for Abeona Therapeutics Inc. (ABEO) for FY2025, with the revenue forecasts being adjusted by -78.03% over the past three months. During the same period, the stock price has changed by -29.32%.
arrow icon

How many employees does Abeona Therapeutics Inc (ABEO). have?

Abeona Therapeutics Inc (ABEO) has 136 emplpoyees as of December 05 2025.

arrow icon

What is Abeona Therapeutics Inc (ABEO) market cap?

Today ABEO has the market capitalization of 263.64M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free